(4R)-4-benzyl-3-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one | 1000415-73-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (4R)-4-benzyl-3-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one
• 英文别名: (4R)-4-benzyl-3-[(E)-3-(4-chlorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one
• CAS: 1000415-73-5
• 化学式: C₁₉H₁₆ClNO₃
• 分子量: 341.794
• InChiKey: DRRQORJNXFYQBQ-VGMNTSGFSA-N

物化性质

• 沸点：
  478.6±47.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R)-4-benzyl-3-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one 、 N-(甲氧甲基)-N-(三甲基硅甲基)苄胺 在 三氟乙酸 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以46%的产率得到(4R)-4-benzyl-3-{[(3R,4S)-1-benzyl-4-(4-chlorophenyl)pyrrolidin-3-yl]carbonyl}-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor

  摘要：

  A series of trans-4-phenylpyrrolidine-3-carboxamides were synthesized and characterized as potent ligands of the human melanocortin-4 receptor. Interestingly, a pair of diastereoisomers 20f-1 and 20f-2 displayed potent functional agonist and antagonist activity, respectively. Thus, the 3S, 4R-compound 20f-1 possessed a K-i of 11 nM and an EC50 of 24 nM, while its 3R, 4S-isomer 20f-2 exhibited a K-i of 8.6 and an IC50 of 65 nM. Both compounds were highly selective over other melanocortin receptor subtypes. The MC4R agonist 20f-1 also demonstrated efficacy in diet-induced obese rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.079
• 作为产物：
  描述：

  对氯肉桂酸 、 (R)-4-苄基-2-噁唑烷酮 在 三甲基乙酰氯 、 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以93%的产率得到(4R)-4-benzyl-3-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor

  摘要：

  A series of trans-4-phenylpyrrolidine-3-carboxamides were synthesized and characterized as potent ligands of the human melanocortin-4 receptor. Interestingly, a pair of diastereoisomers 20f-1 and 20f-2 displayed potent functional agonist and antagonist activity, respectively. Thus, the 3S, 4R-compound 20f-1 possessed a K-i of 11 nM and an EC50 of 24 nM, while its 3R, 4S-isomer 20f-2 exhibited a K-i of 8.6 and an IC50 of 65 nM. Both compounds were highly selective over other melanocortin receptor subtypes. The MC4R agonist 20f-1 also demonstrated efficacy in diet-induced obese rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.079

文献信息

• Nitrogen-containing heterocyclic compound and use of same
  申请人：Shirai Junya

  公开号：US08592454B2

  公开（公告）日：2013-11-26

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

  本发明涉及一种化合物，其表示为以下式子： 其中，环A是含氮杂环；环B是芳香环，可选地具有取代基；环D是芳香环，可选地具有取代基；L是以下式子表示的基团： 其中，R2、R3、R4a和R4b各自独立地是氢原子、可选卤代的C1-6烷基或可选卤代的C3-6环烷基，或者R2和R3通过烷基链或烯基链连接，或者R4a和R4b通过烷基链或烯基链连接；R1是氢原子或取代基；m和n各自独立地是0至5的整数；m+n是2至5的整数；是单键或双键，或其盐；等等。该化合物具有优良的缩氨酸受体拮抗作用，可用作预防或治疗各种疾病的药物，例如下尿路疾病、消化道疾病、中枢神经系统疾病等。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2336105B9

  公开（公告）日：2014-09-17
• US8592454B2
  申请人：——

  公开号：US8592454B2

  公开（公告）日：2013-11-26
• USRE48334E1
  申请人：——

  公开号：USRE48334E1

  公开（公告）日：2020-12-01